Bristol-Myers Squibb Company announced that it has registered in Russia a new indication for the immuno-oncological drug Opdivo® (nivolumab), namely, as a monotherapy for common or recurrent cancer of the stomach or esophageal-gastric transition after 2 or more lines of systemic therapy.
The incidence of gastric cancer in Russia is 95 cases per 100,000 population. In 2018, 21,279 new cases of stomach cancer were detected.
“Systemic therapy for stomach cancer remains a daunting and urgent task. Today we have options for treating patients in the first and second lines, but for patients with progression after two lines of therapy there is no effective approach to treatment. The new indications for the use of nivolumab will change treatment approaches and prospects for patients with advanced and recurring gastric cancer,”
said A.A. Fedenko, MD, head of the department of drug treatment of tumors at P. A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia.
Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.
Opdivo’s leading global development program is based on Bristol-Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients. The Opdivo trials have contributed to gaining a deeper understanding of the potential role of biomarkers in patient care, particularly regarding how patients may benefit from Opdivo across the continuum of PD-L1 expression.